TLR7 and graft versus host disease: TLR7 ligand imiquimod was shown to increase alloreactivity of host-derived DCs and Langerhans cells (LCs) in the skin and to enhance donor lymphocyte infusions (DLIs)-mediated GVHD in MHC-matched multiple minor antigen-mismatched model of BMT (37).